drugset / Trial / NCT00546637

Fesoterodine "add-on" Male Overactive Bladder Study

NCT00546637

Phase 3 Completed 947 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy and safety of fesoterodine on overactive bladder symptom improvement when added to ongoing alpha blocker treatment.

Timeline

Start
2007-11
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Fesoterodine Other / unclassified 4 mg
Subject Fesoterodine Other / unclassified 8 mg

Indications